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Abstract
Stickler syndrome is a genetic disorder that can lead to joint problems, hearing difficulties and retinal detachment. Genes
encoding collagen types II, IX and XI are usually responsible, but some families have no causal variant identified. We
investigate a variant in the gene encoding growth factor BMP4 in a family with Stickler syndrome with associated renal
dysplasia. Next generation sequencing of the coding region of COL2A1, COL11A1 and a panel of genes associated with
congenital anomalies of the kidney and urinary tract (CAKUT) was performed. A novel heterozygous BMP4 variant causing
a premature stop codon, c. 130G>T, p.(Gly44Ter), which segregated with clinical features of Stickler syndrome in multiple
family members, was identified. No variant affecting gene function was detected in COL2A1 or COL11A1. Skin fibroblasts
were cultured with and without emetine, and the mRNA extracted and analysed by Sanger sequencing to assess whether the
change was causing nonsense-mediated decay. Nonsense-mediated decay was not observed from the extracted BMP4
mRNA. BMP4 is a growth factor known to contribute to eye development in animals, and gene variants in humans have
been linked to microphthalmia/anophthalmia as well as CAKUT. The variant identified here further demonstrates the
importance of BMP4 in eye development. This is the first report of a BMP4 DNA variant causing Stickler syndrome, and we
suggest BMP4 be added to standard diagnostic gene panels for this condition.
Introduction
Stickler syndrome is a genetic disorder affecting the eyes,
joints, hearing and orofacial development. It is associated
with a significantly increased lifetime risk of rhegmato-
genous retinal detachment and is the most common cause of
non-traumatic retinal detachment in children. Other ocular
features include myopia, often severe, and congenital
defects of the vitreous, which can be a useful diagnostic
feature and helps direct genetic testing [1, 2]. Hearing loss,
present in 63% of patients, is usually high frequency sen-
sorineural loss, with a variable conductive component in
children due to intermittent otitis media [3]. Joint problems,
in 75%, include hypermobility and premature osteoarthritis
leading to chronic back pain and early joint replacement
surgery [4]. Orofacial manifestations include cleft palate
(41%), Pierre Robin sequence (24%) and midfacial hypo-
plasia [5, 6]. There is, however, marked variability in
the degree to which each system is affected in different
patients [6].
Most cases of Stickler syndrome are due to variants in
genes encoding various fibrillar collagens. Type 1 Stickler
syndrome is the most common, accounting for ~80% of
the cases, and is due to heterozygous changes in COL2A1
(ref. 2), which encodes the alpha-1 chain of type II
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collagen. It carries the greatest risk of retinal detachment,
but generally milder hearing loss. Type 2 Stickler syn-
drome is caused by heterozygous alteration to COL11A1
(ref. 7), which encodes the alpha-1 chain of type XI col-
lagen. Type 3 Stickler syndrome is caused by hetero-
zygous changes to COL11A2 (ref. 8), which is not
expressed in the eye, resulting in a non-ocular phenotype.
There is an ocular-only variant caused by variants in
COL2A1 affecting exon 2 (ref. 9), which is only expressed
in the eye. Less frequently, recessive Stickler syndrome
has been found to be caused by homozygous variants in
COL9A1 (ref. 10), COL9A2 (ref. 11) and COL9A3 (ref. 12),
and bi-allelic COL11A1 sequence changes [13].
Stickler syndrome has been associated with
recessive variants in two non-collagen genes: one
family with a homozygous variant in LOXL3 (ref. 14),
which encodes an enzyme involved in collagen cross-
linking and one family with a homozygous variant in
LRP2 (ref. 15), encoding an endocytic transmembrane
receptor.
The bone morphogenetic proteins (BMPs) are growth
factors that are part of the TGF-β superfamily [16]. They
are expressed throughout embryogenesis and have diverse
roles in development. Initially identified and named for
their role in osteogenesis, they are now recognised to have
a crucial role in early embryonic development in gas-
trulation and neurulation, mesoderm patterning, and cell
proliferation, differentiation and morphogenesis in many
organ systems. BMP4 is known to have a critical role in
ocular development in establishing the dorsal-ventral axis
of the developing eye [17] as well as lens induction and
retinal development [18]. Humans with loss-of-function
variants in BMP4 have previously been described with
highly variable manifestations, including anophthalmia/
microphthalmia, syndactyly and structural brain anoma-
lies including thinning of the corpus callosum and
widened cerebral sulci [19, 20]. Deletions of the 14q22-
q23 region, which includes BMP4 as well as OTX2, also
known to be important for eye development, have been
described causing anophthalmia/microphthalmia and also
hearing problems, Pierre-Robin sequence, developmental
delay and cleft palate [21–23]. Mice models with bmp4
loss-of-function variants have features including micro-
phthalmia, craniofacial anomalies, polydactyly and con-
genital anomalies of the kidney and urinary tract (CAKUT)
[24].
In this study, we investigate a family with clinical fea-
tures of Stickler syndrome, but in which one member of the
family also had congenital renal dysplasia leading to renal
replacement therapy at a young age. Next generation
sequencing identified a sequence variant in the gene for
BMP4, which segregated with the Stickler syndrome phe-
notype in this family.
Patient data
One male, aged 20, with renal dysplasia requiring renal
replacement therapy was referred to clinical genetics
(Patient III:1 in Fig. 1, Table 1). It was noted that several
family members had a clinical diagnosis of Stickler syn-
drome, with five affected members over two generations
(Patients I:1, I:2, II:1, II:3, II:4 in Fig 1, Table 1). Previous
sequencing of the COL2A1 and COL11A1 genes in one of
the affected family members had not identified a variant that
would affect function. The clinical features present in the
family included high myopia, congenital hypoplasia of the
vitreous, retinal detachment, sensorineural hearing loss
(Fig. 2), retrognathia and high-arched palate (Fig. 3). As a
result, this patient was referred to the National Stickler
syndrome diagnostic service, which confirmed that he also
had myopia with abnormal vitreous architecture. Two fur-
ther family members were examined (III:2 and III:3), of
which one had myopia with abnormal vitreous and the other
had normal ophthalmological examination. No other family
members reported kidney disease. Renal ultrasound was
offered but was declined.
Methods
Genetic analysis
Next generation sequencing was performed using the Tru-
Sight One sequencing kit (Illumina, Cambridge, United


















Fig. 1 Family pedigree. Patients clinically affected are in solid. *
Ophthalmologically evaluated clinically (Martin Snead and Thomas
Nixon). E+ DNA evaluated as positive for familial BMP4 variant. E−
DNA evaluated as negative for familial BMP4 variant
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CAKUT (see supplementary information) were identified.
99.69% of the target sequence within this panel was
sequenced to a depth of 20-fold or more, with analytical
sensitivity of 98.3%–100% (95% Confidence Intervals).
Further analysis identified a heterozygous loss-of-function
variant in the BMP4 (NM_001202.3) gene: c.130G>T, p.
(Gly44Ter). DNA variant analysis conformed to best prac-
tice guidelines [25]. Sanger sequencing was used to confirm
the sequence change and to analyse additional family
members. These variants were submitted to the LOVD
database and can be found at www.LOVD.nl/BMP4
(patient IDs 155750, 165221, 165222, 165224 and 165225).
mRNA analysis
RNA was extracted using RNeasy column, (Qiagen, Man-
chester, United Kingdom) from cultured dermal fibroblasts
(family member II-3), that had been incubated either with or
without emetine, an inhibitor of nonsense-mediated decay
(as previously described) [26]. Reverse-transcription PCR
was performed using Superscript II Reverse Transcriptase
(Invitrogen, Hemel Hempstead, United Kingdom) and an
antisense primer: 5′-TGTAGTGTGTGGGTGAGTG
GATGG-3′. PCR amplification was then performed of a
940 bp region of the BMP4 cDNA surrounding the variant,
using Q5 High-fidelity DNA polymerase (NEB, Hitchin,
United Kingdom) in reaction conditions as recommended
by the manufacturer. A primary reaction used primers 5′-
ATGATTCCTGGTAACCGAATGCTG-3′ in exon 3, and
5′-ACCTTATCATACTCATCCAGGTAC-3′ in exon 4.
Products from this primary reaction were then re-amplified
in a secondary reaction using primers 5′-ATTATGC
CAAGTCCTGCTAGGAGG-3′ in exon 3, and 5′-
GGGCCACAATCCAGTCATTCCAGC-3′ in exon 4. The
resulting cDNA product was sequenced using the primer 5′-
ATGTTCTTCGTGGTGGAAGCTC-3′ using standard
methods for Sanger sequencing.
Results
Sequencing
Next generation sequencing of the patient identified a het-
erozygous sequence change in the BMP4 gene:
NM_001202.3: c.130G>T, p.(Gly44Ter). This is predicted
to cause a premature termination codon. Sanger sequencing
confirmed that this variant was present in family members
with the Stickler syndrome phenotype and not present in
those with a normal phenotype (Fig. 4). The sequence






















































































































































































































































































































































































































































































































































































































Bone morphogenetic protein 4 (BMP4) loss-of-function variant associated with autosomal dominant. . . 371
mRNA analysis
Sanger sequencing of the RT-PCR products demonstrated
that both variant and wild-type sequences were present
(Fig. 5) demonstrating that the variant did not result in
nonsense-mediated decay, but would result in a severely
truncated protein.
Discussion
We have described a novel variant in a gene, BMP4,
associated with a Stickler syndrome phenotype. The vast
majority of patients with dominant Stickler syndrome are
found to have COL2A1 or COL11A1 variants [2], and in our
experience less than 5% of patients that have a clear clinical
II:1 Audiogram (age 41) II:3 Audiogram (age 40)
II:4 Audiogram (age 38) III:3 Audiogram (age 19)
Fig. 2 Audiograms. Pure tone audiometry thresholds for patients II:1, II:3, II:4 and III:3
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diagnosis have no detectable variants that affect function in
either of these two genes, or those encoding type IX col-
lagen. This is the first description of a BMP4 gene variant
associated with a clinical phenotype of Stickler syndrome
and is the first non-collagen sequence change found to be
associated with dominant Stickler syndrome, although
recessive Stickler or Stickler-like syndromes have been
described in two other non-collagen genes, LOXL3 (ref. 14)
and LRP2 (ref. 15). One consanguineous family with two
children diagnosed with Stickler syndrome, cleft palate,
micrognathia and congenital high myopia were found to
have a homozygous change in LOXL3, which encodes the
enzyme lysyl oxidase-like 3. Lysyl oxidase-like 3 is known
to cross-link type II collagen, which underlines the funda-
mental collagenopathy in Stickler syndrome. A further
consanguineous family with two children diagnosed with
Stickler syndrome, with congenital high myopia, hypo-
plastic vitreous, a possible vitreous membranous anomaly
similar to type 1 Stickler syndrome, giant retinal tear
detachment and joint hypermobility, were found to have a
homozygous change in LRP2. LRP2 encodes lipoprotein
receptor-related protein-2, an endocytic transmembrane
receptor. Variants in LRP2 are known to cause Donnai–
Barrow syndrome, a rare autosomal recessive disorder
featuring agenesis of the corpus callosum, sensorineural
hearing loss, facial dysmorphism and ocular findings,
including myopia and coloboma. The pathway to cause
Stickler syndrome is less clear in this gene, but it likely
interferes with intercellular signalling during
embryogenesis.
Like other members of the TGF-β superfamily, BMP4 is
synthesised as a precursor molecule and is proteolytically
cleaved into two domains, an N-terminal prodomain,
(which can vary in length due to different transcripts) and a
C-terminal active growth factor dimer forming region [27].
As well as homodimers, BMP4 also forms heterodimers
with BMP7, with the heterodimers being more active [28].
Heterozygous BMP7 loss-of-function variants have also
been associated with anophthalmia [29].
With a 24 amino acid signal peptide, the c. 130G>T, p.
(Gly44Ter) [transcript variant NM_001347912.1;
c.271G>T, p.(Gly91Ter)] variant we describe here results in
only 19 (or 66 from the longer transcript, Fig. 6) amino
acids of the BMP4 prodomain being expressed (the mRNA
does not undergo nonsense-mediated decay). This may
explain why, when compared with previously described
BMP4 variants, the ocular phenotype in this family is mild.
The majority of documented BMP4 loss-of-function var-
iants have severe ocular anomalies, including anophthalmia,
microphthalmia, and anterior chamber abnormalities with
congenital glaucoma [19–23]. Systemic features are vari-
able and include developmental delay, brain and pituitary
Fig. 3 Clinical photographs of patient II:3. a Right lateral facial photograph of patient II:3 demonstrating retrognathia. b Intra-oral photograph of
patient II:3 demonstrating high-arched palate
Bone morphogenetic protein 4 (BMP4) loss-of-function variant associated with autosomal dominant. . . 373
anomalies, craniofacial dysmorphism, kidney anomalies
and polydactyly. Those previously described variants
associated with disease were downstream of the variant in
the pedigree described here. It is possible, therefore, that
those changes produced an abnormal protein with a domi-
nant negative effect, not present in this pedigree, which in
this case may simply reflect haploinsufficiency of BMP4
(due to lack of functional protein from severe truncation).
Interestingly the c.171dupC, p.(Glu58Argfs*17)
[NM_001347912.1; c.312dupC, p.(Glu105Argfs*17)]
BMP4 variant only encodes an additional 14 normal amino
acids of the prodomain yet that change results in a severe
ocular phenotype [20]. BMP4 prodomains can form a stable
interaction with the active domains and alter their affinity
with extracellular matrix molecules [28]. The difference in
resulting phenotypes between c. 130G>T, p.(Gly44Ter) and
c.171dupC, p.(Glu58Argfs*17) may therefore reflect the
ability of these truncated prodomains to form a complex
with growth factor dimers and produce a dominant-negative
effect. It is interesting to contrast the microphthalmia/
anophthalmia seen in previously described BMP4 variants
with the megalophthalmos and myopia seen in this
pedigree.
Another mechanism that potentially modifies the phe-
notype, which needs to be considered is that not all BMP4
transcripts contain the variant described here (Fig. 6).
Transcripts NM_001347913.1, NM_001347915.1,
NM_001347917.1, all have the initiating methionine
downstream of the c.130G>T variant and do not encode the
first 63 amino acids of the NM_01202.3 transcript. How-
ever, this is also true for the c.171dupC p.(Glu58Argfs*17)
variant and so is unlikely to be a major consideration.
A number of cases involve microdeletions, including
BMP4 and adjacent genes in the 14q22–23 region. OTX2 is
only 2.8 Mbs from BMP4 and is also critical in eye
II:1 II:3 II:4
III:1 III:2 III:3
Fig. 4 Sequencing chromatographs for tested family members. Chromatographs demonstrating a heterozygous G>T BMP4 substitution (arrowed)
in affected family members, with no substitution (arrowed) in unaffected family member (III:2)
Wild type:
A B






Fig. 5 Sequencing chromatograph from RT-PCR. a Sanger sequencing
of RT-PCR products (sense orientation) demonstrating heterozygosity
in mRNA extracted from untreated (- emetine) cultured dermal
fibroblasts at the variant locus, i.e. nonsense-mediated decay does not
take place. The G>T variant (arrowed) changes a GGA coding a
glycine residue into a premature stop codon. b Agarose gel of PCR
products. S size ladder. E− sample from cells cultured without eme-
tine, E+ sample from cells cultured with emetine. PCR products are of
expected cDNA size of ~1 kb
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development, with variants also known to cause micro-
phthalmia/anophthalmia. Concurrent deletions of both
genes have been associated with microphthalmia/anoph-
thalmia with decreased cerebral white matter volume [30].
BMP4 has been shown to be critical in establishing the
dorsal-ventral axis of the developing eye [17]. In the chick
eye, bmp4 is expressed in the dorsal optic cup and is
responsible for spatiotemporal co-ordination of apoptotic
cell death [31]. In Xenopus, bmp4 has been shown to act via
inducing tbx5 to determine the dorsal region of the optic
cup, with the factor sonic hedgehog having an opposing
effect [17]. In mouse embryos, increased levels of bmp4
were shown to reduce retinal volume, alter the shape of the
optic cup and reduce axial length—this suggests that low
levels of BMP4 could contribute to increased axial length
and therefore congenital myopia [32]. BMP4 is also critical
for lens induction [19].
The interaction between BMP4 and TGFβ1 may be
important in its role in pathogenesis of retinal detachment. It
is known that exon 2 of COL2A1, expressed in the eye and
developing cartilage but not mature cartilage, encodes a
region of type II procollagen with a cysteine-rich domain
that binds TGFβ1 and BMP2 (ref. 33). Loss-of-function
variants in COL2A1 cause type 1 Stickler syndrome, with
vitreous anomaly and significant risk of retinal detachment.
Additionally, intronic sequence variants affecting the
alternative splicing efficiency of exon 2 of COL2A1 have
been associated with an increased risk of retinal detachment
[34]. BMP4 and BMP2 have significant structural similarity
so it is possible that BMP4 can also bind to type II collagen
[35]. TGFβ1 has also been shown to bind to type IV col-
lagen [36]. This is an important structural component of the
inner limiting membrane of the retina, which then con-
tributes to the posterior hyaloid membrane of the vitreous
[37], which if too adherent to the retina can cause a retinal
tear leading to retinal detachment. Fibrillin is a major
component of microfibrils in extracellular matrices, and
variants in the fibrillin gene (FBN1) can cause Marfan
syndrome, which has many features including myopia and
risk of retinal detachment. It has been shown that mice
deficient in fibrillin have dysregulation of TGFβ1 (ref. 38).
It has also been demonstrated that fibrillin assemblies have a
role in directing signalling through TGFβ1 and BMP
pathways [39]. This may suggest that TGFβ1 dysregulation
may be a ‘final common pathway’ in the pathogenesis of
retinal detachment in patients with a genetic predisposition.
The c.130G>T BMP4 variant was initially identified in
the proband through testing a panel of genes known to be
associated with CAKUT. No other family members are
known to have renal disease but detailed imaging has not
been carried out in all individuals who have the BMP4
variant. The aetiology of CAKUT is complex. A family
history of CAKUT is found in about 10 to 20% of cases but
only a minority will have an identifiable genetic cause
identified. Where a genetic cause is identified, the pattern of
inheritance and segregation of the disease phenotype typi-
cally appears as an autosomal dominant trait with incom-
plete penetrance and variable expression. This marked
variability, also seen in animal models of CAKUT, may be

















Fig. 6 BMP4 transcripts and variant positions. The BMP4 gene con-
sists of four exons. Transcription can start at multiple locations on the
gene. All variants are described relative to their position on transcript
NM_01202.3. Three different BMP4 transcripts are shown, demon-
strating the position of the c.130G>T variant compared with those
previously described. Transcript NM_001347913.1 is unaffected by
this variant. All previously described variants are downstream of the
variant described in this paper and all affect the NM_001347913.1
transcript, except c.171dupC
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variants that do not completely disrupt early nephrogenesis
but affect renal and urinary tract development at later stages
of gestation and genetic or environmental modifiers [40].
In summary, a BMP4 variant has been identified as a
cause of autosomal dominant Stickler syndrome. Molecular
genetic diagnosis is important for families to allow appro-
priate follow-up, risk management advice and genetic
counselling regarding family planning, so testing for BMP4
should be considered in Stickler syndrome where no variant
is identified in a collagen gene that would be expected to
affect function. If a loss-of-function BMP4 variant is iden-
tified in a patient with Stickler syndrome then patients
should be investigated for CAKUT, and conversely if
identified in a patient with CAKUT, they should be referred
for ophthalmological assessment.
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